Ranexa™ for Chronic Angina An Unmet Need

Slides:



Advertisements
Similar presentations
بسم الله الرحمن الرحيم. Current Treatment of Stable Angina By Ahmed Shafea Ammar MD, FACC.
Advertisements

Cardiology Morning Report: Revascularization in Stable Ischemic Heart Disease Bobby Mathew, MD LSU Internal Medicine, HO-II.
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 51 Drugs for Angina Pectoris.
Can we prevent stent restenosis after coronary stent implantation
British Cardiac Intervention Society Risk Assessment In Acute Coronary Syndromes Dr David Newby BHF Senior Lecturer in Cardiology Associate Director of.
Improving survival in symptomatic ischemic patients with left ventricular dysfunction Beneficial effects of long-term trimetazidine* therapy Fragasso G.
The ERICA Trial Peter H. Stone, MD, FACC, Nikolay A. Gratsiansky, MD, Alexey Blokhin, MD, I-Zu Huang, MD, Lixin Meng, MS, MPH, for the ERICA Investigators.
Chronic stable angina Dr Taban Internist & cardiologist.
David J. Cohen, Tara A. Lavelle, Patrick W. Serruys, Friedrich W. Mohr, Haiyan Li, Yang Lei, Kaijun Wang, Kate Robertus, Elizabeth M. Mahoney, Yueping.
Ischemic heart disease
Ischemic Heart Diseases IHD
Orlando, Florida – October 7, 2011 Cardiac Rehab: Improving Outcomes One Step at a Time Martha Gulati MD, MS, FACC, FAHA Associate Professor of Medicine.
1 Dr. Zahoor Ali Shaikh. 2 CORONARY ARTERY DISEASE (CAD)  CAD is most common form of heart disease and causes premature death.  In UK, 1 in 3 men and.
COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)
1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.
SIGN CHD In Scotland in the year ending 31 March 2006 over 10,300 patients died from CHD and 5,800 from cerebrovascular disease, with.
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Coronary Artery Disease Angina Pectoris Unstable Angina Variant Angina Joseph D. Lynch, MD.
Myocardial Ischemia Redefined: Optimal Care in CAD.
Cardiovascular Disease in Women Module V: Prognosis and Treatment Outcomes.
1 1 The Use of Percutaneous Coronary Intervention in Patients with Class I Indications for Coronary Artery Bypass Graft Surgery: Data from the National.
Ten Points to Remember from the 2007 STEMI Guideline Update Based on the 2007 Focused Update of the 2004 Guidelines for the Management of Patients With.
CR-1 1 Ranolazine Benefit/Risk Jeremy N. Ruskin, MD, FACC.
Management of Chronic Stable Angina AIMGP Seminar Series Mirek Otremba 2007.
Redefining Treatment Strategies for Optimal Medical Care in CAD COURAGE and MERLIN-TIMI 36.
Benefits of adding a energetic agent to  -blockers to achieve optimal reduction of angina. Review of the main studies.
RITA-3 Is this a benign lesion in a benign condition? Who Needs Angioplasty in 2008? Stable Angina Stable Angina Keith A A Fox Professor of Cardiology.
Silent Ischemia STABLE CAD
Aspirin Resistance: Significance, Detection and Clinical Management of This Real Phenomenon Webcast May 10 th, 2004 Sponsored by.
Cardiac Rehabilitation 2011 Update for Primary Care Providers Douglass A Morrison, MD, PhD Cardiac Rehabilitation, Medical Director Yakima Regional and.
OVERALL SURVIVAL Adapted from Scandinavian Simvastatin Survival Study Group Lancet 1994;344: % of patients alive Simvastatin (n=2221)
The Synergy between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery: The SYNTAX Study One Year Results of the PCI and CABG Registries.
Clinical Management of Chronic Stable Angina. Anti-ischemic strategies in stable CAD Medical therapyPCICABG Initial therapy Recurrent ischemia TMREECPSCS.
American Heart Association. Available at Accessed February
Diabetes Mellitus 101 for Cardiologists (and Alike): 2015
Community Outreach to Reduce Disparities in Cardiovascular & Diabetes Morbidity & Mortality in the South Bronx Michael Alderman, MD Michelle Johnson, MD,
Effects of Ranolazine: from Angina to Cardiac Performance Iacopo Olivotto, MD Referral Center for Cardiomyopathies Careggi University Hospital Florence,
 Heart disease remains the leading cause of morbidity and mortality in industrialized nations.  40% of all deaths in the U.S.A (nearly twice the number.
Effects of Ranolazine on Angina and Quality of Life Following PCI with Incomplete Revascularization -- The Ranolazine for Incomplete Vessel Revascularization.
Efficacy of Ranolazine In Chronic Angina trial
Acute Coronary Syndromes Risk-Stratification Pathophysiology Diagnosis Initial Therapy Risk-Stratification Risk-Stratification Invasive vs Conservative.
Contemporary Management of Myocardial Ischemia
Bangalore S, et al. β-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308(13): ?
? What more will it take to turn the tide of treatment for angina patients from a PCI-first to an optimal medical therapy– first approach? 1.
Can we improve the management of angina patients after percutaneous coronary intervention? Beneficial effects of adding trimetazidine MR therapy after.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc.1 Drugs for Angina Pectoris.
Ten Year Outcome of Coronary Artery Bypass Graft Surgery Versus Medical Therapy in Patients with Ischemic Cardiomyopathy Results of the Surgical Treatment.
Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Cardiovascular Surgery J Am Coll Cardiol.
Drugs for Angina Pectoris
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: ACC/AHA guidelines for percutaneous coronary intervention.
Date of download: 9/18/2016 Copyright © The American College of Cardiology. All rights reserved. From: Presidential address: quality of cardiovascular.
Prof. Dr. med. Sigmund Silber Cardiology Practice and Hospital
The MASS-DAC Study.
CORONARY ARTERY DISEASE
Patient populations by study group figure 10
Clinical need for determination of vulnerable plaques
Women, Bleeding, and Coronary Intervention
Catheter-Based Treatment of Coronary Artery Disease
Nursing Management: Patients With Coronary Vascular Disorders
Glenn N. Levine et al. JACC 2016;68:
Prevalence of statin and beta-blocker use by clinical presentation
The following slides highlight a report on a presentation at a Late-Breaking Trial Session of the European Society of Cardiology Congress 2004 held in.
O.L.Reuchlin gebruik van CT binnen de cardiogie
ARISE Trial Aggressive Reduction of Inflammation Stops Events
Cox regression of proportion mortality in the first 8 years for patients with three-vessel disease with a significant difference between the treatment.
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
MRRs and EMRRs for women with ACS
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Cardiovascular Epidemiology and Epidemiological Modelling
Presentation transcript:

Ranexa™ for Chronic Angina An Unmet Need 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Ranexa™ for Chronic Angina An Unmet Need Eugene Braunwald, MD, FACC Harvard Medical School Brigham and Women’s Hospital

2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM CM-2 There is a strong disorder in the breast. The seat of it, and sense of strangling and anxiety with which it is attended, may make it not improperly be called angina pectoris.… Those who are afflicted with it, are seized, while they are walking with a painful and most disagreeable sensation in the breast, which seems as if it would take their life away, if it were to increase or to continue. Heberden. Medical Transaction, Royal College of Physicians of London. 1772;2:59-67.

Epidemiology of Chronic Angina 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Epidemiology of Chronic Angina AHA reports that at least 6.6 million Americans suffer with angina pectoris Despite therapeutic advances > 13 million episodes of angina a week in the US > 1000 episodes of angina every minute Growing prevalence of chronic angina due to reductions in cardiovascular mortality Improved treatment of angina is an important goal

Comorbid Conditions Complicate Therapy 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Comorbid Conditions Complicate Therapy Studies of VA patients with CAD demonstrate the following comorbidity incidence rates Diabetes: 26% to 31% COPD: 13% to 22% Peripheral vascular disease: 16% to 28% Congestive heart failure: 20% Rumsfeld, 1999.

Persistent Angina Despite Current Drug Therapy 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Persistent Angina Despite Current Drug Therapy Despite use of traditional anti-anginal agents (-blockers, CCBs, and nitrates), patients still reported an average of 2 anginal attacks/week† A significant percentage of patients have relative intolerance to full doses of -blockers, CCBs, and nitrates -blockers and many CCBs have similar depressive effects on BP, HR and/or AV nodal conduction It would be desirable to develop an anti-anginal drug without these limitations †Pepine, 1994.

Persistent Angina Despite Percutaneous Intervention (PCI) 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Persistent Angina Despite Percutaneous Intervention (PCI) Angina at 1-yr follow-up by events during or after initial PCI 1 yr after PCI for. . . Symptom relief (N = 1403) Treatment of acute myocardial infarction (N = 352) . . . the overall prevalence of angina was 26% Events, n Angina at follow-up, % Events occurring after post-PCI discharge only MI No 1576 25.2 Yes 44 38.6 CABG 1522 26.3 98 15.3 Repeat PCI 1370 24.1 250 34.0 Holubkov R, et al. NHLBI Dynamic Registry. Am Heart J. 2002;144:826-833.

Persistent Angina Despite Optimal Revascularization 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Persistent Angina Despite Optimal Revascularization 1 yr after optimal revascularization by stenting or surgery for relief of ischemia (ie, not to prolong survival) … TABLE 3. STATUS WITH RESPECT TO ANGINA AND MEDICATION USE AND QUALITY OF LIFE AMONG SURVIVING PATIENTS.* VARIABLE 12 MO AFTER INTERVENTION STENTING GROUP SURGERY GROUP P value Free of angina (%) 78.9 89.5 <0.001 Free of antianginal medication (%) 21.1 41.5 Free of angina and antianginal medication (%) 19.1 38.4 ~ 60% to 80% are still taking anti-anginal medications ~ 10% to 20% still have angina Serruys PW, et al. for the ARTS Study Group. N Engl J Med. 2001;344:1117-1124.

Self Rating of Health for Angina Patients 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Self Rating of Health for Angina Patients 100 Normal US population Angina patients 90 80 General health 70 Vitality 60 SF36 scores 50 40 30 20 10 Physical function Bodily pain Chen AY, et al. Med Decis Making. 1996;16:169-177.

Angina Frequency and Depression 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Angina Frequency and Depression 1957 patients completed SAQ 7 mo after ACS History of depression documented in 526 (26.7%) patients following ACS Strong correlation of angina frequency with depression 50 45 40 35 30 % depression 25 20 15 10 5 None Monthly Weekly Daily Angina frequency ACS = acute coronary syndrome SAQ = Seattle Angina Questionnaire Rumsfeld JS, et al. Am Heart J. 2003;145:492.

Unmet Need of Chronic Angina 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Unmet Need of Chronic Angina Angina continues in many patients despite medical therapy and mechanical revascularization The personal burden can deprive many patients of their functional independence, forcing them to downsize their lives The economic toll of angina places a huge burden on patients, their families, the healthcare system, and society

Unmet Need of Chronic Angina 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Unmet Need of Chronic Angina When angina cannot be eliminated by current drugs, it is often their additive effects on BP, HR, AV conduction, and other important side effects (depression, fatigue, sexual/sleep disorders, etc.) that preclude complete relief.

Novel Therapies Needed for a Growing Angina Burden 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Novel Therapies Needed for a Growing Angina Burden 6 4 Patients, millions 2 1900 2000

Angina—Evolution of Therapy 2. Chronic Angina—An Unmet Need (CM) 4/13/2017 4:00 PM Angina—Evolution of Therapy Nitrates  block CABG CCB PCI Ranexa™ TREATMENT 1880 1965 1969 1975 1977 2004 O2 demand + + + O2 supply + + ? + ATP/O2 + Likely mechanisms